Zai Lab Current Ratio 2016-2021 | ZLAB

Current and historical current ratio for Zai Lab (ZLAB) from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Zai Lab current ratio for the three months ending June 30, 2021 was 9.33.
Zai Lab Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.81B $0.19B 9.33
2021-03-31 $1.05B $0.09B 11.32
2020-12-31 $1.22B $0.10B 12.40
2020-06-30 $0.49B $0.06B 8.57
2020-03-31 $0.00B 0.00
2019-12-31 $0.29B $0.05B 6.27
2019-09-30 $0.33B $0.04B 8.02
2019-06-30 $0.40B $0.05B 8.74
2018-12-31 $0.27B $0.05B 5.51
2017-12-31 $0.23B $0.01B 19.11
2017-06-30 $0.09B $0.01B 9.76
2016-12-31 $0.08B $0.01B 16.26
2015-12-31 $0.01B $0.00B 3.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.038B $0.049B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86